Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service EP ablation cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 99 | 5,046 | 46% |
| 2020 | 81 | 4,428 | 48% |
| 2021 | 105 | 5,843 | 51% |
| 2022 | 120 | 6,547 | 53% |
| 2023 | 124 | 6,842 | 55% |
| 2024 | 138 | 7,854 | 57% |
| 2025 from claims | – | 9,915 9,099–10,490 | 58% |
| 2026 forecast | – | 10,852 9,548–12,523 | 58% |
| 2027 forecast | – | 11,835 10,117–14,103 | 59% |
| 2028 forecast | – | 12,904 10,767–15,801 | 59% |
| 2029 forecast | – | 14,068 11,490–17,643 | 60% |
| 2030 forecast | – | 15,335 12,285–19,651 | 60% |
AF, SVT, and VT catheter ablation. Professional codes (what the surgeon bills): CPT 93656, 93653, 93654; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 24% of the cases CMS names in New York; 72 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 31% inpatient hospital, 69% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 131 | 5,803+11%/yr | +11%/yr | 3.5 | 0% | 11,400 in 2030+12%/yr |
| Massachusetts | 73 | 4,222+12%/yr | +12%/yr | 4.0 | 0% | 9,560 in 2030+15%/yr |
| New Jersey | 61 | 3,055+5.7%/yr | +5.7%/yr | 2.5 | 0% | 5,460 in 2030+10%/yr |
| Connecticut | 25 | 921+6%/yr | +6%/yr | 2.3 | 0% | 1,750 in 2030+11%/yr |
| New Hampshire | 11 | 595+16%/yr | +16%/yr | 2.3 | 0% | 1,590 in 2030+18%/yr |
| Maine | 10 | 404+10%/yr | +10%/yr | 2.1 | 0% | 870 in 2030+14%/yr |
| Rhode Island | 8 | 382+4.9%/yr | +4.9%/yr | 3.4 | 0% | 920 in 2030+16%/yr |
| Vermont | 6 | 187+11%/yr | +11%/yr | 1.5 | 0% | 630 in 2030+22%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| LAA occlusion & loop recorders | 191 | 8,988+5.9%/yr | +5.9%/yr | 4.31.5× | 12% | 14,400 in 2030+8.1%/yr |
| Pacemaker, ICD & CRT implantation | 148 | 8,138−3%/yr | −3%/yr | 4.70.9× | 0% | 8,390 in 2030+0.5%/yr |
EP ablation in every state, and its device makers · Every procedure market in New York · Every state · Compare with Pennsylvania
Johnson & Johnson MedTech leads with 41% of company spending on these surgeons in 2025, −10 pts on 2024.
In 2025, 8 companies reported engagement with New York’s surgeons worth $1.2M in consulting, speaking, meals and travel tied to these products, about $8,514 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 102 clearances and approvals in the category, 5 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
New York’s own discharge file counts every inpatient stay, whatever the payer: 4,796 cardiac ablation stays at 36 hospitals in 2024, against the Medicare-only figures above. The most commercial of the busy ones is NEW YORK-PRESBYTERIAN HOSPITAL (41% commercial): where commercial rates leave the most room for a premium product.
| Hospital | Cases | Medicare | Commercial |
|---|---|---|---|
| SOUTH SHORE UNIVERSITY HOSPITAL BAY SHORE | 498 | 62% | 31% |
| LENOX HILL HOSPITAL NEW YORK | 456 | 58% | 33% |
| STATEN ISLAND UNIVERSITY HOSPITAL STATEN ISLAND | 408 | 59% | 32% |
| NORTH SHORE UNIVERSITY HOSPITAL MANHASSET | 344 | 64% | 29% |
| NYU LANGONE HOSPITALS NEW YORK | 332 | 69% | 22% |
| NEW YORK-PRESBYTERIAN HOSPITAL NEW YORK | 262 | 47% | 41% |
| MOUNT SINAI WEST NEW YORK | 248 | 63% | 32% |
| LONG ISLAND JEWISH MEDICAL CENTER NEW HYDE PARK | 216 | 45% | 36% |
New York only: MedaRep has no other state’s all-payer file yet. Counted by principal procedure (Cardiac ablation: procedures on the heart's conduction system.). Medicare here includes Medicare Advantage. A hospital with 10 or fewer such stays, or a payer share of 10 or fewer, is not shown. Source: New York State Department of Health, SPARCS de-identified inpatient discharges (health.data.ny.gov). The New York State Department of Health makes no representation, warranty or guarantee relating to the data or analyses derived from these data. Accessed 2026-11-11.